Bladder and Urothelial Cancer Treatments
Bladder and Urothelial Cancer Treatments is a research topic within Surgery. Science Explorer counts 42k research works in it since 1950. 18.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis, treatment, and management of bladder cancer, particularly urothelial carcinoma. It covers topics such as chemotherapy, cystectomy, neoadjuvant therapy, molecular characterization, metastatic bladder cancer, guidelines for management, and immunotherapy. The papers provide insights into various aspects of bladder cancer research and clinical practice.
- Bladder Cancer
- Urothelial Carcinoma
- Chemotherapy
- Cystectomy
- Bacillus Calmette-Guerin
- Molecular Characterization
- Neoadjuvant Therapy
- Metastatic Bladder Cancer
- Guidelines
- Immunotherapy
- Research works
- 42k fractional, since 1950
- In the world top 10%
- 7.6k per year above
- Top-10% rate
- 18.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +31% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Bladder and Urothelial Cancer Treatments research?
By volume, the United States and China publish the most (1.9k and 1.6k works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.9k works
- 2 China 1.6k works
- 3 Japan 530 works
- 4 Germany 377 works
- 5 Italy 364 works
- 6 United Kingdom 307 works
- 7 India 268 works
- 8 France 259 works
- 9 Spain 186 works
- 10 South Korea 181 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Bladder and Urothelial Cancer Treatments research?
By volume in 2022–2025, Memorial Sloan Kettering Cancer Center publishes the most Bladder and Urothelial Cancer Treatments research, followed by The University of Texas MD Anderson Cancer Center and Peking University.
By volume, 2022–2025
- 1 Memorial Sloan Kettering Cancer CenterUnited States 52 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 47 works
- 3 Peking UniversityChina 37 works
- 4 Sun Yat-sen UniversityChina 35 works
- 5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 33 works
- 6 Cleveland ClinicUnited States 33 works
- 7 Sichuan UniversityChina 33 works
- 8 Istituti di Ricovero e Cura a Carattere ScientificoItaly 31 works
- 9 University of North Carolina at Chapel HillUnited States 30 works
- 10 Icahn School of Medicine at Mount SinaiUnited States 29 works
Where is Bladder and Urothelial Cancer Treatments research done?
The largest centres of Bladder and Urothelial Cancer Treatments research in 2022–2025 are Beijing (China), New York (United States), Shanghai (China) and Tokyo (Japan).
Largest cities, 2022–2025
Where is the best place to study Bladder and Urothelial Cancer Treatments?
Among universities, judged by research, Icahn School of Medicine at Mount Sinai, Vita-Salute San Raffaele University and Medical University of Vienna score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Icahn School of Medicine at Mount SinaiUnited States | 68.9 | 27.8% | 8.0× | 29 | +155.3% |
| 2 | Vita-Salute San Raffaele UniversityItaly | 65.5 | 31.7% | 21.2× | 21 | -17.1% |
| 3 | Medical University of ViennaAustria | 61.7 | 25.2% | 8.1× | 19 | +86.8% |
| 4 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 53.4 | 22.9% | 4.5× | 33 | +108.3% |
| 5 | Jikei University School of MedicineJapan | 51.2 | 23.9% | 14.7× | 10 | — |
| 6 | Queen Mary University of LondonUnited Kingdom | 51.0 | 29.1% | 3.1× | 10 | +197.0% |
| 7 | Wroclaw Medical UniversityPoland | 50.6 | 21.8% | 7.2× | 8 | +307.3% |
| 8 | Peking UniversityChina | 50.0 | 18.5% | 3.1× | 37 | +121.7% |
| 9 | Sun Yat-sen UniversityChina | 49.8 | 24.8% | 2.8× | 34 | +86.0% |
| 10 | Kunming Medical UniversityChina | 48.8 | 22.4% | 10.9× | 15 | -37.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Bladder and Urothelial Cancer Treatments research growing?
Output in 2018–2022 was 31% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Bladder and Urothelial Cancer Treatments.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.